HJB - Your Trusted Biologics CDMO Partner
HJB, CDMO, biologics, HJB Bio, hjbbio, China CDMO, 杭州奕安济世, Just Bio, Just biotherapeutics, HJB bio, HJB China, Hangzhou HJB
Sep, 2020
HJB, a biologics CDMO located in Hangzhou, announced a successful GMP bi-specific antibody perfusion process at 200L scale for a client.
"This is an important milestone at HJB as we develop and implement highly productive perfusion platform using in-house developed chemically defined media," said Dr. Chris Hwang, Head of Platform Technology of HJB. "Given the high volumetric productivity of our perfusion processes, typical pre-pivotal clinical demand can be met with<200L scale single use bioreactor (SUB) while commercial supply can be met with 500L scale SUB."
This is another key milestone for HJB's perfusion platform after achieving productivity to greater than 4 g/L per day for multiple cell lines earlier this year. With continuous technological innovations, HJB is committed to providing high quality, very reliable and fast CDMO service for each and every CMC package delivered to its biologics' partners.
GMP run with perfusion process at HJB facility
BD@hjbbio.com
